Since Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) in 2010, biosimilars have bolstered competition and increased options for patients. As more biosimilars and interchangeable biosimilars are anticipated to enter the market in the years ahead, competition and savings are expected to grow substantially. But more can be done to realize the full potential of the biosimilar marketplace by addressing market distortions that impede more robust competition and savings from biosimilars, particularly when they could offer lower out-of-pocket costs for patients.